-
公开(公告)号：KR101795999B1
公开(公告)日：2017-11-09
申请号：KR1020150136069
申请日：2015-09-25
Applicant: 전남대학교산학협력단
Abstract: 본발명의 CRISPR/CAS9 시스템을이용한베타2-마이크로글로불린유전자제거방법및 이에사용되는시발체는베타2-마이크로글로불린유전자만이선택적으로정확히제거되도록특별히디자인됨으로써, 비표적유전자에는영향을주지않으면서표적유전자인베타2-마이크로글로불린유전자만이특이적으로정확하게제거되어제거효율이현저하게향상되는효과가있다.
-
公开(公告)号：KR1020140056474A
公开(公告)日：2014-05-12
申请号：KR1020120119507
申请日：2012-10-26
Applicant: 전남대학교산학협력단
Abstract: The present invention relates to an isolating method of a leukemia stem cell at the single cell level and a culturing method of the leukemia stem cell that is isolated at the single cell level. According to the present invention, a single leukemia stem cell is isolated based on an immune cell marker finding and a clone of the single leukemia stem cell is obtained by culturing the single leukemia stem cell on a certain badge. Moreover, the leukemia stem cell isolated at the single cell level and the cultured leukemia stem cell can be used to develop a new medicine and an immune molecule marker which target the leukemia stem cell.
Abstract translation: 本发明涉及在单细胞水平的白血病干细胞的分离方法和在单细胞水平分离的白血病干细胞的培养方法。 根据本发明，基于免疫细胞标志物发现分离单一白血病干细胞，通过在某一标记上培养单一白血病干细胞获得单一白血病干细胞的克隆。 此外，在单细胞水平分离的白血病干细胞和培养的白血病干细胞可用于开发靶向白血病干细胞的新药和免疫分子标记。
-
公开(公告)号：KR1020180008836A
公开(公告)日：2018-01-24
申请号：KR1020180004442
申请日：2018-01-12
Applicant: 전남대학교산학협력단
IPC: C12Q1/68
CPC classification number: Y02A50/451 , C12Q1/6888 , C12Q1/686 , C12Q2561/113 , C12Q2600/16
Abstract: 본발명은위장관장애를일으키는장내기생충검출용키트및 이를이용한기생충검출방법에관한것이다. 본발명에따른프라이머와프로브, 이를포함하는실시간중합효소연쇄반응증폭용키트는장내기생충검출시, 우수한검출한계, 특이도, 높은신뢰성을보이고, 이는종래의현미경적진단법보다더 민감한검출이가능하므로임상적으로매우유용하게사용될수 있다.
Abstract translation: 本发明涉及用于检测引起胃肠道疾病的肠道寄生虫的试剂盒以及使用其的寄生虫检测方法。 根据本发明的引物和探针以及包含其的实时PCR扩增用试剂盒当检测肠道寄生虫时显示出优异的检测极限，特异性和高可靠性，这使得比常规显微诊断更灵敏的检测 它可以在临床上非常有用地使用。
-
14.发明公开프로히비틴 단백질에 대한 항체를 포함하는 혈액암 진단용 조성물 및 이를 포함하는 혈액암 진단용 키트 审中-实审一种血液癌诊断用组合物，其特征在于，含有抗原原体水
蛋白蛋白质的抗体和诊断血癌的试剂盒公开(公告)号：KR1020170096377A
公开(公告)日：2017-08-24
申请号：KR1020160017689
申请日：2016-02-16
Applicant: 전남대학교산학협력단 , 동신대학교산학협력단
IPC: G01N33/574 , G01N33/532 , G01N33/543
Abstract: 본발명은프로히비틴단백질에대한항체를포함하는혈액암진단용조성물및 이를포함하는혈액암진단용키트에관한것이다. 본발명에따른프로히비틴단백질에특이적으로결합하는것을특징으로하는혈액암진단용조성물은종래프로히비틴분석용키트에사용된조성물보다검출항체의농도가낮음에도불구하고, 프로히비틴검출능이매우우수하며, 특히프로히비틴-2 발현정도를빠르게확인할수 있고, 진단의정확도및 재현성이높아혈액암진단, 바람직하게백혈병진단, 백혈병잔류병소측정또는백혈병치료효과판정용키트로유용하게사용될수 있다.
Abstract translation: 本发明涉及含有抗蛋白酶蛋白质的抗体的血癌诊断用组合物和含有其的血癌诊断用试剂盒。 血液癌症诊断组合物，其特征在于，根据本发明，尽管比在锡分析试剂盒用于低和亲日比锡检测能力的组合物与现有技术的亲日比检测抗体的浓度的特异性结合亲日比锡蛋白 和非常好的，尤其是亲日比锡和可以快速确定程度-2表达中，可以使用增加的精度和诊断有用作为血液癌症，优选白血病诊断，白血病或白血病肿瘤残留测定试剂盒用于治疗性决定的可再现性 有。
-
公开(公告)号：KR101745863B1
公开(公告)日：2017-06-12
申请号：KR1020150136075
申请日：2015-09-25
Applicant: 전남대학교산학협력단
Abstract: 본발명의 CRISPR/CAS9 시스템을이용한프로히비틴2 유전자제거방법및 이에사용되는시발체는프로히비틴2 유전자만이선택적으로정확히제거되도록특별히디자인됨으로써, 비표적유전자에는영향을주지않으면서표적유전자인프로히비틴2 유전자만이특이적으로정확하게제거되어제거효율이현저하게향상되는효과가있다.
-
Patent Agency Ranking
公开(公告)号：KR1020170037028A
公开(公告)日：2017-04-04
申请号：KR1020150136075
申请日：2015-09-25
Applicant: 전남대학교산학협력단
Abstract: 본발명의 CRISPR/CAS9 시스템을이용한프로히비틴2 유전자제거방법및 이에사용되는시발체는프로히비틴2 유전자만이선택적으로정확히제거되도록특별히디자인됨으로써, 비표적유전자에는영향을주지않으면서표적유전자인프로히비틴2 유전자만이특이적으로정확하게제거되어제거효율이현저하게향상되는효과가있다.
Abstract translation: 使用本发明的CRISPR / CAS9系统和其中使用的引物去除蛋白酶2基因的方法被特别设计，使得只有蛋白质2基因被选择性和选择性地去除，从而靶基因， 只有特异性和正确地去除了hibitin 2基因，从而显着提高了去除效率。
-
公开(公告)号：KR1020170037025A
公开(公告)日：2017-04-04
申请号：KR1020150136069
申请日：2015-09-25
Applicant: 전남대학교산학협력단
Abstract: 본발명의 CRISPR/CAS9 시스템을이용한베타2-마이크로글로불린유전자제거방법및 이에사용되는시발체는베타2-마이크로글로불린유전자만이선택적으로정확히제거되도록특별히디자인됨으로써, 비표적유전자에는영향을주지않으면서표적유전자인베타2-마이크로글로불린유전자만이특이적으로정확하게제거되어제거효율이현저하게향상되는효과가있다.
Abstract translation: 使用与用于本发明的在其中的方法和系统的引物被专门设计用于选择性地去除完全一样的β2 - 微球蛋白基因只，非靶基因是与靶基因站立而不影响CRISPR / CAS9的β2 - 微球蛋白基因除去 只有特异性且正确地去除了β2-微球蛋白基因，从而显着提高了去除效率。
-
公开(公告)号：KR1020140056472A
公开(公告)日：2014-05-12
申请号：KR1020120119503
申请日：2012-10-26
Applicant: 전남대학교산학협력단
CPC classification number: G01N33/5302 , C12N15/115 , C12N2310/16 , C12Q1/6886 , C12Q2600/158 , G01N33/57426 , G01N33/6857 , G01N33/6893
Abstract: The present invention relates to a kit for leukemia diagnosis or prognosis analysis. Prohibitin (PHB) protein according to the present invention is a marker for leukemia having significantly improved accuracy and reliability. Moreover, according to the present invention, early leukemia diagnosis and prognostic determination can be enabled in a very specific manner through a biological sample (for example, blood or serum) using the PHB protein. The expression of PHB protein specifically increases only in the tissue of a leukemia patient.
Abstract translation: 本发明涉及用于白血病诊断或预后分析的试剂盒。 根据本发明的抑制蛋白（PHB）蛋白是具有显着提高的准确度和可靠性的白血病标记物。 此外，根据本发明，可以通过使用PHB蛋白质的生物样品（例如血液或血清）以非常特定的方式使早期白血病诊断和预后测定成为可能。 PHB蛋白的表达仅在白血病患者的组织中增加。
-
19.发明授权
公开(公告)号：KR100831058B1
公开(公告)日：2008-05-20
申请号：KR1020060110964
申请日：2006-11-10
Applicant: 전남대학교산학협력단
Inventor： 신명근
IPC: C12Q1/68
Abstract: 본 발명은 실시간중합효소연쇄반응(real-time polymerase chain reaction)을 이용하여 JAK2 V617F 돌연변이를 정량적으로 검출하는 방법, 시발체(primers) 및 키트에 관한 것으로서, JAK2 V617F 돌연변이를 비교적 쉽고, 민감하고 정확하게, 정량적으로 검출할 수 있으므로, 만성골수성질환을 비롯한 다양한 골수구성 혈액질환에 있어서 진단, 예후, 치료경과 추정 등에 매우 중요한 의미를 갖는다.
JAK2, V617F, janus kinase 2, 실시간중합효소연쇄반응, 실시간-PCR, 만성골수성질환, 골수구성 혈액질환-
20.发明授权실시간중합효소연쇄반응 및 유전자 스캔을 이용한미토콘드리아 ＤＮＡ 4977 ｂｐ 거대결손의 정량적검출방법, 시발체 및 키트 有权使用实时PCR和基因扫描定量检测MITOCHONDRIAL DNA 4977 BP大量检测的方法，引物和试剂盒
公开(公告)号：KR100789475B1
公开(公告)日：2008-01-02
申请号：KR1020060114288
申请日：2006-11-20
Applicant: 전남대학교산학협력단
Inventor： 신명근
IPC: C12Q1/68
CPC classification number: C12Q1/6851 , C12Q1/686 , C12Q2561/113
Abstract: A method for quantitatively detecting large deletion of mitochondrial DNA 4977bp is provided to sensitively, accurately and quantitatively detect the mitochondrial DNA 4977bp through a real-time PCR and a gene scan, thereby being used for diagnosing, prognosing and estimating the treatment progress of tumor and chronic degenerative diseases. A method for quantitatively detecting large deletion of mitochondrial DNA 4977 bp comprises the steps of: (a) performing a real-time PCR and a melting-reaction on a total DNA extracted using a forward primer of SEQ ID : NO. 1 and a reverse primer of SEQ ID : NO. 2 regarding a deleted mitochondria DNA(mtDNA), and a forward primer of SEQ ID : NO. 3 and a reverse primer of SEQ ID : NO. 4 regarding a complete mitochondria DNA to obtain an amplification period of the deleted mitochondria DNA and the complete mitochondria, respectively; (b) performing a PCR on the total DNA extracted from the step(a) to perform a gene scan, thereby obtaining a peak area of the deleted mitochondria and the complete mitochondria, respectively; and (c) calculating the frequency of the large deletion of the mitochondria DNA 4977 by an equation(1) of f(dmtDNA) = Admt/Amtx1.9608^CDmtx1.9613^CDdmtx123/113(wherein f(dmtDNA)) is the frequency of the 4977bp large deletion, Admt is the peak area of the deleted mtDNA, Amt is the peak area of the complete mtDNA, CDmt is the amplification period of the complete mtDNA, and the CDdmt is the amplification period of the deleted mtDNA.
Abstract translation: 提供定量检测线粒体DNA 4977bp的大量缺失的方法，通过实时PCR和基因扫描对线粒体DNA 4977bp进行敏感，准确，定量的检测，从而用于诊断，预测和估计肿瘤的治疗进展， 慢性退行性疾病。 定量检测线粒体DNA 4977bp的大量缺失的方法包括以下步骤：（a）对使用SEQ ID NO：1的正向引物提取的总DNA进行实时PCR和融合反应。 1和SEQ ID NO：1的反向引物。 2关于缺失的线粒体DNA（mtDNA）和正向引物SEQ ID NO： 3和SEQ ID NO：1的反向引物。 4关于完整的线粒体DNA分别获得缺失的线粒体DNA和完整的线粒体的扩增期; （b）对从步骤（a）提取的总DNA进行PCR以进行基因扫描，从而分别得到缺失的线粒体和完整的线粒体的峰面积; （c）通过f（dmtDNA）= Admt / Amtx1.9608 ^ CDmtx1.9613 ^ CDdmtx123 / 113（其中f（dmtDNA））的方程（1）计算线粒体DNA 4977的大量缺失的频率 频率为4977bp的大缺失，Admt是缺失mtDNA的峰面积，Amt是完整mtDNA的峰面积，CDmt是完整mtDNA的扩增周期，CDdmt是缺失的mtDNA的扩增期。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.047 seconds)
